Hidradenitis Suppurativa study: ORKA-002
Official title ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
ClinicalTrials.gov ID: NCT07783542
What this study is testing
What is ORKA-002?
ORKA-002 is an investigational injectable medicine being studied as a potential treatment for moderate-to-severe hidradenitis suppurativa.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if ORKA‑002 is safe and works for people with moderate‑to‑severe hidradenitis suppurativa.
- Who it's for
- Adults who have moderate‑to‑severe hidradenitis suppurativa.
- What's involved
- Participants will receive either ORKA‑002 or a placebo and will attend scheduled visits for treatment and health checks.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 79
You may be able to join if
- Has signs and symptoms of HS for at least 6 months;
- Has HS lesions present in ≥ 2 distinct anatomic areas, one of which must be at least Hurley Stage II or III;
- Has a history of inadequate response to systemic antibiotic treatment for HS, exhibited recurrence of HS symptoms after discontinuation of systemic...
You likely can't join if
- Presence of any other active skin disease or condition that may interfere with the assessment of HS;
- Diagnosis or suspected diagnosis of autoimmune diseases or inflammatory conditions other than HS
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Fountain Valley, California, United States
- Los Angeles, California, United States
- Cromwell, Connecticut, United States
- Sandy Springs, Georgia, United States
- Chicago, Illinois, United States
- Plainfield, Indiana, United States
- Baton Rouge, Louisiana, United States
- New Orleans, Louisiana, United States
- Canton, Michigan, United States
- New Brighton, Minnesota, United States
- St Louis, Missouri, United States
- Omaha, Nebraska, United States
- New York, New York, United States
- Chapel Hill, North Carolina, United States
- Portland, Oregon, United States
- Smyrna, Tennessee, United States
- Dallas, Texas, United States
- Missouri City, Texas, United States
- San Antonio, Texas, United States
+ 5 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 79 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Fountain Valley, California, United States; Los Angeles, California, United States; Cromwell, Connecticut, United States; Sandy Springs, Georgia, United States; Chicago, Illinois, United States and 19 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.